Content
09/23/2024
Washington, DC USA
VerImmune
completed $4.5 million Series A Round funding. Investors include
Beiley Biofund Inc., Gaingels, Mana Ventures, Proxima VC.
About
VerImmune is advancing Anti-tumor Immune Redirection (AIR):
A Breakthrough Therapy that Redirects Pre-Existing Immune Memory
from Childhood Vaccination or Infection to Fight Cancer
Startup
Sector:
Biotech
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
